Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.